Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1977 Dec;36(6):743–750. doi: 10.1038/bjc.1977.257

Intense tumour-cell destruction by syngeneic mice: role of macrophages, complement activation and tumour-cell factors.

S Orbach-Arbouys, J Lheritier, M Allouche, P Pouillart
PMCID: PMC2025552  PMID: 145872

Abstract

When injected i.p. and in large numbers (10(7)) into syngeneic mice, 125IUdR-labelled L1210 cells are rapidly destroyed in a small proportion of animals, while in the other animals the lysis is low. This bimodal distribution is clearly visible 24 h after cell injection. The intense lysis occurs in fewer animals when macrophage-derived lysosomal enzymes are inhibited by trypan blue and if the complement is depleted by high doses of cobra venom factor (CVF). The intense destruction occurs in more animals after adjuvant treatment, if the mice are latently contaminated, after a moderate production of C3b by low doses of CVF, or after the injection of a tumour-cell dialysate. The destruction seems to be the result of positive feedback reaction which involves at least macrophages and complement activation.

Full text

PDF
743

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentley C., Bitter-Suermann D., Hadding U., Brade V. In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages. Eur J Immunol. 1976 Jun;6(6):393–398. doi: 10.1002/eji.1830060604. [DOI] [PubMed] [Google Scholar]
  2. Biran H., Moake J. L., Reed R. C., Gutterman J. U., Hersh E. M., Freireich E. J., Mavligit G. M. Complement activation in vivo in cancer patients receiving C. parvum immunotherapy. Br J Cancer. 1976 Nov;34(5):493–499. doi: 10.1038/bjc.1976.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bitter-Suermann D., Burger R., Brade V., Hadding U. Mouse factor B of the alternative pathway of complement activation. I. Purification, characterization, and functional behavior. J Immunol. 1976 Nov;117(5 PT2):1799–1804. [PubMed] [Google Scholar]
  4. Brade V., Nicholson A., Bitter-Suermann D., Hadding U. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes. J Immunol. 1974 Dec;113(6):1735–1743. [PubMed] [Google Scholar]
  5. Ferluga J., Schorlemmer H. U., Baptista L. C., Allison A. C. Cytolytic effects of the complement cleavage product, C3a. Br J Cancer. 1976 Dec;34(6):626–634. doi: 10.1038/bjc.1976.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hibbs J. B., Jr Activated macrophages as cytotoxic effector cells. Transplantation. 1975 Jan;19(1):77–81. doi: 10.1097/00007890-197501000-00015. [DOI] [PubMed] [Google Scholar]
  7. Hibbs J. B., Jr, Lambert L. H., Jr, Remington J. S. Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol. 1972 Jan 12;235(54):48–50. doi: 10.1038/newbio235048a0. [DOI] [PubMed] [Google Scholar]
  8. Hofer K. G., Prensky W., Hughes W. L. Death and metastatic distribution of tumor cells in mice monitored with 125I-iododeoxy-uridine. J Natl Cancer Inst. 1969 Oct;43(4):763–773. [PubMed] [Google Scholar]
  9. Martin S. E., Martin W. J. Anti-tumour antibodies in normal mouse sera. Int J Cancer. 1975 Apr 15;15(4):658–664. doi: 10.1002/ijc.2910150415. [DOI] [PubMed] [Google Scholar]
  10. Ménard S., Colnaghi M. I., Porta G. D. Natural anti-tumor serum reactivity in BALB/c mice. I. Characterization and interference with tumor growth. Int J Cancer. 1977 Feb 15;19(2):267–274. doi: 10.1002/ijc.2910190217. [DOI] [PubMed] [Google Scholar]
  11. Norbury K. C., Fidler I. J. In vitro tumor cell destruction by syngeneic mouse macrophoages: methods for assaying cytotoxicity. J Immunol Methods. 1975 Apr;7(1):109–122. doi: 10.1016/0022-1759(75)90136-2. [DOI] [PubMed] [Google Scholar]
  12. Pepys M. B. Role of complement in induction of the allergic response. Nat New Biol. 1972 May 31;237(74):157–159. doi: 10.1038/newbio237157a0. [DOI] [PubMed] [Google Scholar]
  13. Pierotti M. A., Colnaghi M. I. Natural antibodies directed against murine lymphosarcoma cells. J Natl Cancer Inst. 1975 Oct;55(4):945–949. doi: 10.1093/jnci/55.4.945. [DOI] [PubMed] [Google Scholar]
  14. Pierotti M. A., Colnaghi M. I. Natural antibodies directed against murine lymphosarcoma cells: variability of level in individual mice. Int J Cancer. 1976 Aug 15;18(2):223–229. doi: 10.1002/ijc.2910180212. [DOI] [PubMed] [Google Scholar]
  15. Pike M. C., Snyderman R. Depression of macrophage function by a factor produced by neoplasms: a merchanism for abrogation of immune surveillance. J Immunol. 1976 Oct;117(4):1243–1249. [PubMed] [Google Scholar]
  16. Porteous D. D., Munro T. R. The kinetics of the killing of mouse tumour cells in vivo by immune responses. Int J Cancer. 1972 Jul 15;10(1):112–117. doi: 10.1002/ijc.2910100115. [DOI] [PubMed] [Google Scholar]
  17. Reif A. E., Kim C. A. Leukemia L1210 therapy trials with antileukemia serum and Bacillus Calmette-Guérin. Cancer Res. 1971 Nov;31(11):1606–1612. [PubMed] [Google Scholar]
  18. Sadler T. E., Alexander P. Trapping and destruction of blood-borne syngeneic leukaemia cells in lung, liver and spleen of normal and leukaemic rats. Br J Cancer. 1976 May;33(5):512–520. doi: 10.1038/bjc.1976.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schorlemmer H. U., Allison A. C. Effects of activated complement components on enzyme secretion by macrophages. Immunology. 1976 Nov;31(5):781–788. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES